Hanmi Science Co., Ltd. (KRX:008930)
28,450
-3,200 (-10.11%)
Jun 8, 2026, 3:30 PM KST
Hanmi Science Revenue
Hanmi Science had revenue of 375.62B KRW in the quarter ending March 31, 2026, with 6.70% growth. This brings the company's revenue in the last twelve months to 1.38T, up 4.96% year-over-year. In the year 2025, Hanmi Science had annual revenue of 1.36T with 5.73% growth.
Revenue (ttm)
1.38T
Revenue Growth
+4.96%
P/S Ratio
1.40
Revenue / Employee
2.90B
Employees
476
Market Cap
1.93T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.36T | 73.53B | 5.73% |
| Dec 31, 2024 | 1.28T | 35.53B | 2.85% |
| Dec 31, 2023 | 1.25T | 201.85B | 19.30% |
| Dec 31, 2022 | 1.05T | 95.89B | 10.09% |
| Dec 31, 2021 | 950.16B | 92.78B | 10.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Samsung Epis Holdings | 1.51T |
| Hugel | 451.93B |
| ST Pharm | 346.22B |
| Celltrion Pharm | 274.73B |
| ALTEOGEN | 203.76B |
| Oscotec | 101.55B |